Long-term Study of SYR-472

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Hypoglycemic Agents

Criteria

Inclusion Criteria:

1. The participant is an outpatient.

2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

3. Diabetes Mellitus

Exclusion Criteria:

1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.

2. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.